Search results for: Cancer
Filter search results
NGS testing for lung cancer across Europe still limited, despite clear case for adoption
10 July 2023
…for expanding its use in lung cancer. Coupled with potential efficiency savings, and a chance to improve patient outcomes, the case for investing in NGS strengthens.” Lung cancer affects hundreds…
What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment
2 January 2020
…of cancer on the NHS: around 90-95 percent of patients suspected of having cancer are not diagnosed with cancer. However, all potential cancer patients proceed along the same cancer pathway…
Achieving World Class Outcomes in Cancer Treatment
1 July 2011
The speaker for the OHE’s 16th Annual Lecture was Sir Mike Richards, National Clinical Director for Cancer and End of Life Care in England’s Department of Health. In his presentation,…
OHE Lunchtime Seminar: How Cost-Effective are New Cancer Drugs in the U.S.?
2 August 2017
…measured as the ratio of the impact of new cancer drugs on medical expenditure to their impact on the number of years of potential life lost due to cancer. The…
Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
10 June 2024
…we can ensure that development efforts lead to much-needed advances in oncology diagnostics, for the benefit of cancer patients. Find out more here: https://www.cancerresearchuk.org/funding-for-researchers/research-opportunities-in-early-detection-and-diagnosis/early-detection-and-diagnosis-roadmap Read the full report here: https://www.cancerresearchuk.org/sites/default/files/final_report_31may2024_final.pdf…
Limits to Using QALYs in Cancer
3 August 2010
…health that often are very important to cancer patients. Valuation of health states for cancer patients using traditional methods also encounters problems. For example, the time trade-off (TTO) method assumes that…
Comparing the EQ-5D-3L and EQ-5D-5L in a Cohort of Cancer Patients: A Research Collaboration between OHE, Curtin University and King’s College London
15 August 2017
…evaluated in HTA decisions. The project will analyse data from Cancer 2015, a large-scale longitudinal genomic cancer cohort study in Victoria, Australia. Cancer 2015 enrols newly diagnosed, treatment naïve cancer…
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
…cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for widespread access. Key takeaways Next-generation sequencing (NGS) testing for lung cancer provides more…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
1 April 2019
…Health Assembly WHA70.12 on Cancer prevention and control in the context of an integrated approach. The WHO Technical Report: Pricing of cancer medicines and its impacts (“the Report”) was published…